Wordt geladen...
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy
For the past decade, docetaxel has remained the global standard of care for frontline treatment of metastatic castration-resistant prostate cancer (mCRPC). Until recently, there were limited options for patients with mCRPC following docetaxel failure or resistance, but now the approved treatment cho...
Bewaard in:
| Gepubliceerd in: | Oncogene |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876694/ https://ncbi.nlm.nih.gov/pubmed/24276248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2013.497 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|